Isonatraemic haemodialysis in the management of salt and water overload: a crossover trial at an academic hospital in Dakar, Senegal

  • Moustapha Faye Department of Nephrology at Aristide Le Dantec Hospital, Cheikh Anta Diop University
  • Bacary Ba Department of Nephrology at Aristide Le Dantec Hospital, Cheikh Anta Diop University
  • Niakhaleen Keita Department of Nephrology at Aristide Le Dantec Hospital, Cheikh Anta Diop University
  • Sidy Mohamed Ba Department of Nephrology at Aristide Le Dantec Hospital, Cheikh Anta Diop University
  • Cheikh Ahmed Tidiane Coulibaly Department of Nephrology at Aristide Le Dantec Hospital, Cheikh Anta Diop University
  • Ibrahima Thioune Department of Nephrology at Aristide Le Dantec Hospital, Cheikh Anta Diop University
  • Maria Faye Department of Nephrology at Aristide Le Dantec Hospital, Cheikh Anta Diop University
  • Ahmed Tall Lemrabott Department of Nephrology at Aristide Le Dantec Hospital, Cheikh Anta Diop University
  • Abdou Niang Department of Nephrology at Aristide Le Dantec Hospital, Cheikh Anta Diop University
  • Elhadji Fary Ka Department of Nephrology at Aristide Le Dantec Hospital, Cheikh Anta Diop University
Keywords: isonatraemic haemodialysis, interdialytic weight gain, blood pressure, Senegal

Abstract

Introduction: The aims of this study were to assess the impact of isonatraemic haemodialysis on reduction of interdialytic weight gain (IDWG) and blood pressure (BP) as well as its tolerability in our study population. Methods: This crossover trial, at the Aristide Le Dantec University Hospital in Senegal, was conducted on 32 patients with kidney failure who were stable on treatment with chronic haemodialysis. In the initial “control phase”, patients had nine haemodialysis sessions with a dialysate sodium (Na+) concentration (Na+ dialysate) of 138 mmol/L. The serum Na+ set point (SP) for each patient was calculated from three predialytic mid-week values. In the second phase, the “individualized phase”, patients had nine haemodialysis sessions with Na+ dialysate equal to their SP. Results: The mean age of the patients was 55.5 ± 12.1 years, with a male/female ratio of 1.3 and the most common cause of kidney disease was hypertension (47%). Mean predialytic serum Na+ concentration was 135.8 ± 1.9 mmol/L, with a mean intra-individual coefficient of variation of 2%. Mean interdialytic weight gain (IDWG) was 1.9 kg and 1.8 kg in the control and individualized phases, respectively (P = 0.75). A reduction in postdialytic systolic blood pressure (BP) was observed during the individualized phase (P = 0.04). A similar trend was noted in pre- and intradialytic BP but this was not statistically significant. Apart from headaches, which were more common in the individualized phase (P = 0.04), isonatraemic haemodialysis was well tolerated. Conclusions: IDWG as well as pre- and intradialytic BP were unaffected by isonatraemic haemodialysis. Postdialytic BP was significantly reduced. Introduction: Les objectifs de cette étude étaient d’évaluer l’impact de l’hémodialyse isonatrémique sur la réduction de la prise de poids inter-dialytique (PPID) et de la pression artérielle (PA) ainsi que sa tolérance dans notre population d’étude. Méthodes: Cet essai croisé a été mené au centre hospitalier universitaire Aristide Le Dantec de Dakar (Sénégal) chez des patients hémodialysés chroniques. Durant la première phase dite « phase contrôle », les patients ont eu neuf séances d’hémodialyse avec une concentration de sodium dans le dialysat (Na+ dialysat) de 138 mmol/L. Le set-point (SP) de la natrémie a été calculé pour chaque patient et correspondait à la moyenne de 3 natrémies pré-dialytiques en milieu de semaine. Durant la deuxième phase dite « phase individualisée », les patients ont eu neuf séances d’hémodialyse avec du Na+ dialysat égal à leur SP. Résultats: Trente-deux patients ont été inclus. L’âge moyen était de 55,5 ± 12,1 ans avec un ratio homme/femme de 1,3 et la néphropathie initiale la plus fréquente était l’hypertensive (47%). La natrémie pré-dialytique moyenne était de 135,8 ± 1,9 mmol/L, avec un coefficient de variation intra-individuel moyen de 2 %. La PPID moyenne était de 1,9 kg et 1,8 kg dans les phases de contrôle et individualisé, respectivement (P = 0,75). Une diminution de la PA systolique post-dialytique a été observée au cours de la phase individualisée (P = 0,04). Une tendance similaire sans significativité statistique a été notée sur les PA pré- et intra-dialytiques. Hormis les céphalées, plus fréquentes pendant la phase individualisée (P = 0,04), l’hémodialyse isonatrémique a été bien tolérée. Conclusions: La PPID, les PA pré- et intra-dialytiques n’ont pas été affectées par l’hémodialyse isonatrémique. La PA post-dialytique était significativement réduite.

References

Paoletti E, Specchia C, Di Maio G, Bellino D, Damasio B, Cassottana P et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: A 10-year survey. Nephrol Dial Transplant. 2004; 19:1829-1834.

London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol. 2001; 12:2759-2767.

Thomson B, Li L, Lindsay R. Effect of Personalized Dialysate Sodium Prescription on Plasma Sodium Concentration and Sodium Set Point in Conventional, Quotidian and Nocturnal Home Hemodialysis. J Nephrol Ther 2017, 7:294.

Kayikcioglu M, Tumuklu M, Ozkahya M, Ozdogan O, Asci G, Duman S et al. The benefit of salt restriction in the treatment of end-stage renal disease by hemodialysis. Nephrol Dial Transplant. 2009; 24:956-962.

Ozkahya M, Ok E, Cirit M, Aydin S, Akçiçek F, Basçi A et al. Regression of left ventricular hypertrophy in hemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant. 1998; 13:1489-1493.

Chan CT, Greene T, Chertow GM, Kliger AS, Stokes JB, Beck et al. Determinants of left ventricular mass in patients on hemodialysis: Frequent hemodialysis network (FHN) trials. Circ Cardiovasc Imaging. 2012; 5:251-261.

Rocco MV, Lockridge RS, Beck GJ, Eggers PW, Gassman JJ, Greene T et al. The effects of frequent nocturnal home hemodialysis: The frequent hemodialysis network nocturnal trial. Kidney Int. 2011; 80:1080-1091.

Hur E, Usta M, Toz H, Asci G, Wabel P, Kahvecioglu S et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: A randomized controlled trial. IS J Kidney Dis. 2013; 61:957-965?

Moissl U, Arias-Guillen M, Wabel P, Fontseré N, Carrera M, Campistol JM et al. Bioimpedance-guided fluid management in hemodialysis patients. Clin J Am Soc Nephrol. 2013; 8:1575-1582.

De Paula FM, Peixoto AJ, Pinto LV, Dorigo D, Patricio PJM, Santos SFF et al. Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int. 2004; 66:1232-1238.

Sayarlioglu H, Erkoc R, Tuncer M, Soyoral Y, Esen R, Gumrukcuoglu HA et al. Effects of low sodium dialysate in chronic hemodialysis patients: An echocardiographic study. Ren Fail. 2007; 29:143-146.

Suckling RJ, Swift PA, He FJ, and Markandu ND, MacGregor GA. Altering plasma sodium concentration rapidly changes blood pressure during haemodialysis. Nephrol Dial Transplant. 2013; 28:2181-2186.

Goumri N, Lefebvre MM, Thomas K, Sacquepee M, Amirou M. Bénéfice de la dialyse isonatrique chez les patients de plus de 70 ans. Nephrol Ther. 2016; 12:328.

Petitclerc T, Gaillard F. Hémodialyse isonatrique : principe et modalités. Nephrol Ther. 2019; 15:22-28.

Kooman J, Basci A, Pizzarelli F, Bernard Canaud, Patrick Haage, Denis Fouque, et al. EBPG guideline on haemodynamic instability. Nephrol Dial Transplant. 2007; 22(Suppl 2):ii22–44.

Arramreddy R, Sun SJ, Munoz Mendoza J, Chertow GM, Schiller B. Individualized reduction in dialysate sodium in conventional in-center hemodialysis. Hemodial Int. 2012; 16:473-480.

Radhika C. R, Santosh V, Abitha C, Jacob S, David VG, Alexander S, et al. Effects of Individualized Dialysate Sodium Prescription in Hemodialysis – Results from a Prospective Interventional Trial. Indian J Nephrol. 2020; 30:3-7.

Basile C, Libutti P, Lisi P, Vernaglione L, Casucci F, Losurdo N, et al. Sodium setpoint and gradient in bicarbonate hemodialysis. J Nephrol. 2013; 26:1136-1142.

Keen ML, Gotch FA. The association of the sodium “setpoint” to interdialytic weight gain and blood pressure in hemodialysis patients. Int J Artif Organs. 2007; 30:971-979,

Song JH, Lee SW, Suh CK, Kim MJ. Time-averaged concentration of dialysate sodium relates with sodium load and interdialytic weight gain during sodium-profiling hemodialysis. Am J Kidney Dis. 2002; 40:291-301,

Thein H, Haloob I, Marshall MR. Associations of a facility level decrease in dialysate sodium concentration with blood pressure and interdialytic weight gain. Nephrol Dial Transplant. 2007; 22:2630-2639.

Elshahawy Y, Sany D, Shawky S. Outcome of individualized dialysate sodium concentration for hemodialysis patients. Saudi J Kidney Dis Transplant. 2013; 24:507-513.

Peixoto AJ, Gowda N, Parikh CR, Santos SF. Long-term stability of serum sodium in hemodialysis patients. Blood Purif. 2010; 29:264-267.

Moret K, Aalten J, van den Wall Bake W, Gerlag P, Beerenhout C, Van der Sande F, et al. The effect of sodium profiling and feedback technologies on plasma conductivity and ionic mass balance: a study in hypotension-prone dialysis patients. Nephrol Dial Transplant. 2006; 21:138–144.

Published
2021-07-03
How to Cite
Faye, Moustapha, Bacary Ba, Niakhaleen Keita, Sidy Mohamed Ba, Cheikh Ahmed Tidiane Coulibaly, Ibrahima Thioune, Maria Faye, Ahmed Tall Lemrabott, Abdou Niang, and Elhadji Fary Ka. 2021. “Isonatraemic Haemodialysis in the Management of Salt and Water Overload: A Crossover Trial at an Academic Hospital in Dakar, Senegal”. African Journal of Nephrology 24 (1), 25-30. https://doi.org/10.21804/24-1-4484.
Section
Original articles